Torrent Pharmaceuticals Limited issued a regulatory filing to the stock exchanges (BSE and NSE) on 09th July 2026, enclosing a press release regarding an update on its product, Semalix Injection Disposable Pens.
The company is implementing a voluntary recall as a precautionary measure. This action is limited only to select batches of Semalix injection disposable pens. The recall was initiated following a product recall notification issued by the product's manufacturer, Dr. Reddy's Laboratories Ltd. (DRL), Hyderabad, which was for the purpose of a technical evaluation.
Torrent Pharmaceuticals emphasized that patient safety is its paramount concern. The filing explicitly states that there is no risk to patients who are already on this treatment as a result of this recall.
The scope of the recall is specific. The affected product is Semalix Injection in select batches of the 2 mg and 4 mg strengths, which were manufactured by DRL.
The company clarified that all other stock-keeping units (SKUs) of Semaglutide sold by Torrent remain completely unaffected by this action. The list of unaffected products includes:
- Semalix tablet 3 mg, 7 mg, 14 mg (manufactured by Torrent)
- Sembolic tablet 3 mg, 7 mg, 14 mg (manufactured by Torrent)
- Semalix injection 8 mg (manufactured by MSN Laboratories)
- Sembolic re-usable injection (manufactured by Zydus Lifesciences Ltd.)
The company provided a contact email address, pv@torrentpharma.com, for patients or their family members requiring further clarification if they are being treated with any of the mentioned products.
The letter was signed by Chintan Trivedi, Company Secretary, and was filed pursuant with standard listing regulations.